Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THC/CBD crossover trial for Tourette syndrome
ACTRN12618000545268Phase 2Completed
- Sponsor
- Wesley Research Institute
- Start
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of dronabinol and cannabidiol in Tourette syndrome (TS) (2 arms), sponsored by Wesley Research Institute. Primary endpoint: Mean tic severity difference by Yale Global Tic Severity Scale. Started Mar 2019; status: completed.
02
Drugs
dronabinolcannabidiol
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on ACTRN12618000545268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000545268.